英文摘要 |
Elective Single Embryo Transfer (e-SET) is the implantation method currently promoted by the medical community, as it can help women avoid the health risks associated with multiple pregnancies and the risks to the fetus. Preimplantation Genetic Testing for Aneuploidy (PGT-A) can be a useful tool for selecting high-quality embryos at the current stage of embryo screening. PGT-A can be used to detect extra or missing chromosomes, known as aneuploidy. Most cases of aneuploidy lead to failed embryo implantation or miscarriage. Therefore, the biggest advantage of PGT-A is that it can identify embryos with a higher likelihood of successful, healthy pregnancies before implantation, which can help reduce miscarriage rates and increase pregnancy rates per cycle. However, PGT-A currently has some technical limitations and challenges. When PGT-A results do not show any embryos with whole chromosomes, there is a decision to be made whether to implant mosaic embryos. Also, in order to implant perfect euploid embryos, it may sometimes cause treatment time to be extended. Additionally, the cost-effectiveness of PGT-A is difficult to quantify, as many studies have not considered all the subsequent costs of obstetrics, neonates, and disease/anueploidy. Overall, PGT-A can assist clinicians in choosing high-quality embryos for implantation, which plays a crucial role in improving the utilization rate of e-SET. However, more research is needed to determine whether the monetary and time costs of PGT-A technology are in line with economic benefits. |